EVH vs. TDC, BLKB, DXC, ACLS, SYNA, TSEM, DOCN, AEIS, ASAN, and POWI
Should you be buying Evolent Health stock or one of its competitors? The main competitors of Evolent Health include Teradata (TDC), Blackbaud (BLKB), DXC Technology (DXC), Axcelis Technologies (ACLS), Synaptics (SYNA), Tower Semiconductor (TSEM), DigitalOcean (DOCN), Advanced Energy Industries (AEIS), Asana (ASAN), and Power Integrations (POWI). These companies are all part of the "computer and technology" sector.
Evolent Health (NYSE:EVH) and Teradata (NYSE:TDC) are both mid-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Evolent Health currently has a consensus price target of $42.80, suggesting a potential upside of 30.73%. Teradata has a consensus price target of $57.30, suggesting a potential upside of 45.54%. Given Teradata's higher probable upside, analysts clearly believe Teradata is more favorable than Evolent Health.
In the previous week, Evolent Health and Evolent Health both had 2 articles in the media. Evolent Health's average media sentiment score of 1.46 beat Teradata's score of 0.51 indicating that Evolent Health is being referred to more favorably in the media.
90.3% of Teradata shares are held by institutional investors. 3.3% of Evolent Health shares are held by company insiders. Comparatively, 0.9% of Teradata shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Teradata received 37 more outperform votes than Evolent Health when rated by MarketBeat users. However, 73.73% of users gave Evolent Health an outperform vote while only 58.78% of users gave Teradata an outperform vote.
Evolent Health has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Teradata has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Teradata has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Teradata, indicating that it is currently the more affordable of the two stocks.
Teradata has a net margin of 3.38% compared to Evolent Health's net margin of -5.76%. Teradata's return on equity of 58.25% beat Evolent Health's return on equity.
Summary
Teradata beats Evolent Health on 10 of the 17 factors compared between the two stocks.
Get Evolent Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Evolent Health Competitors List
Related Companies and Tools